arrow
A

Alessandra Vergori

University of Foggia
H指数:31
被引数:4,725

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world evaluation of HIV-1 reservoir and resistance in virologically suppressed people after 52 weeks of treatment with long-acting cabotegravir plus rilpivirine

长期卡博格韦与 rilpivirine 联合治疗52周后病毒学抑制者中HIV-1储库和耐药性的真实世界评估

2026-07-010
PRE
The Forgotten Test: Missed Opportunities for HIV Diagnosis and Survival Outcomes in Advanced HIV Disease

被遗忘的检测:晚期HIV疾病中HIV诊断错失机会与生存结局

Viruses
IF3.5
2026-03-150
OAAI
Supporting equitable booster strategies: one-year real-world immunogenicity data in people with HIV (PWH) receiving different variant-adapted COVID-19 vaccines

支持公平的加强针策略:人类免疫缺陷病毒感染者(PWH)接种不同变体适应型COVID-19疫苗后一年的真实世界免疫原性数据

2025-11-070
OAAI
Determinants of non-compliance with additional booster doses of the SARS-CoV-2 vaccine in people living with HIV (PWH): An observational study based on a behavioral and epidemiological survey in Rome (Italy)

人类免疫缺陷病毒感染者(HIV感染者)未接受SARS-CoV-2疫苗追加加强针的影响因素:一项基于罗马(意大利)行为学和流行病学调查的观察性研究

2025-11-060
OAAI
Inflammatory Milieu and Specific T-Cell Response Observed Three Months and One Year After SARS-CoV-2 Infection in Long COVID Subjects

长期新冠患者感染SARS-CoV-2后三个月和一年观察到的炎症微环境及特异T细胞应答

2025-10-270
OAAI
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort

HIV感染者中一线拉米夫定/多替拉韦抗逆转录病毒疗法的有效性:ICONA基金会队列的真实世界数据

2025-09-010
PRE
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation

病毒学抑制的HIV感染者转换为双药方案与维持三药方案的临朐事件风险:目标试验模拟

2025-07-240
OA
Switching to bictegravir/emtricitabine/tenofovir alafenamide from efavirenz/emtricitabine/tenofovir disoproxil in virologically suppressed people with HIV: findings from a non-randomized clinical trial (EBONY study)

从依非韦伦/恩曲他滨/替诺福韦二吡呋酯转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺,用于病毒学抑制的HIV感染者:一项非随机临床试验(EBONY研究)的结果

2025-06-180
OAAI
Immune Response Against Recent Omicron Sub-Lineages in Persons with HIV Receiving a Protein-Based or mRNA XBB.1.5 SARS-CoV-2 Booster Vaccine

HIV感染者接种基于蛋白或mRNA XBB.1.5 SARS-CoV-2加强疫苗后对近期奥密克戎亚系的免疫应答

2025-04-090
OA
ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV

ORCHESTRA Delphi共识:人类免疫缺陷病毒感染者中严重急性呼吸综合征冠状病毒2型感染的临床管理

2025-03-210
PRE
Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic
2024-11-230
OAAI
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves
2024-11-010
OAAI
Impact of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate to bictegravir/emtricitabine/tenofovir alafenamide on psychiatric symptoms and neurocognition
AIDS
IF3.1
2024-10-240
PRE
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21
2024-07-192
OAAI
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
2024-07-170
OAAI